Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: A colonoscopy controlled prospective cohort study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Oort, Frank A ^a   Van Turenhout, Sietze T ^a   Coupé, Veerle M H ^a   Van Der Hulst, René W M ^b   Wesdorp, Eric I C ^c   Terhaar Sive Droste, Jochim S ^a   Larbi, Ilhame B ^a   Kanis, Shannon L ^a   Van Hengel, Edwin ^a   Bouman, Anneke A ^a   Meijer, Gerrit A ^a   Mulder, Chris J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Gastroenterology and Hepatology   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY CANCER; FECES ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ADENOMA; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; COLONOSCOPY; COLORECTAL TUMOR; EARLY DIAGNOSIS; EVALUATION; FECES; IMMUNOLOGICAL PROCEDURES; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; IMMUNOLOGIC TESTS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 80053595590     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-434     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010,
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781. 10.1016/j.ejca.2009.12.014, 20116997.
3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365-1371.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467-1471. 10.1016/S0140-6736(96)03430-7, 8942774.
5. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477. 10.1016/S0140-6736(96)03386-7, 8942775.
6. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007, 56:210-214. 10.1136/gut.2006.101428, 1856766, 16891354.
7. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology 2008, 135:82-90. 10.1053/j.gastro.2008.03.040, 18482589.
8. Oort FA, Terhaar Sive Droste JS, VAN DER Hulst RW, VAN Heukelem HA, Loffeld RJ, Wesdorp IC, VAN Wanrooij RL, DE BL, Mutsaers ER, VAN DER RS, Coupe VM, Berkhof J, Bouman AA, Meijer GA, Mulder CJ. Colonoscopy controlled intraindividual comparisons to screen relevant neoplasia - fecal immunochemical test versus guaiac based fecal occult blood test. Aliment Pharmacol Ther 2009,
9. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996, 334:155-159. 10.1056/NEJM199601183340304, 8531970.
10. Terhaar Sive Droste JS, Oort FA, VAN DER Hulst RW, VAN Heukelem HA, Loffeld RJ, van Turenhout ST, Ben L, Kanis SL, Neerincx M, Rakers M, Coupe VM, Bouman AA, Meijer GA, Mulder CJ. Higher Fecal Immunochemical Test cut-off levels: lower positivity rates but still acceptable detection rates for early stage colorectal cancers. Cancer Epidemiol Biomarkers Prev 2010,
11. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, Verbeek AL, Dekker E. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009, 101:1274-1281. 10.1038/sj.bjc.6605326, 2768446, 19755997.
12. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007, 146:244-255.
13. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
14. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009, 29:906-917. 10.1111/j.1365-2036.2009.03946.x, 19183147.
15. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, Bortoli A, Castiglione G, Cazzola L, Confortini M, Mantellini P, Rubeca T, Zappa M. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009, 100:259-265.
16. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, Launoy G. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009, 125:1127-1133. 10.1002/ijc.24407, 19431212.
17. Fraser CG, Matthew CM, Mowat NA, Wilson JA, Carey FA, Steele RJ. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol 2006, 7:127-131. 10.1016/S1470-2045(05)70473-3, 16455476.
18. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010,
19. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS. Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening. Am J Gastroenterol 2010,
20. Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, Zhang B. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999, 46:228-231.
21. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006, 12:MT27-MT32.
22. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, Burt RW, Byers T, Fletcher RH, Hyman N, Johnson D, Kirk L, Lieberman DA, Levin TR, O'Brien MJ, Simmang C, Thorson AG, Winawer SJ. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006, 56:160-167. 10.3322/canjclin.56.3.160, 16737948.
23. Greene Fea AJCC (American Joint Committee on Cancer) Cancer Staging Manual. Springer-Verlag 2002, 113. vol New York, Greene Fea.
24. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001, 345:555-560. 10.1056/NEJMoa010328, 11529208.
25. Altman D. Practical statistics for medical research; Chapman&Hall/CRC. 1991, 409-413.
26. Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future?. Ann Intern Med 2007, 146:309-311.
27. Brenner H, Haug U, Hundt S. Sex differences in performance of fecal occult blood testing. Am J Gastroenterol 2010, 105:2457-2464. 10.1038/ajg.2010.301, 20700114.
28. van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Meijer G, Jansen JB, Dekker E, Mulder CJ. Is the performance of a faecal occult blood test really different in a referred population compared with a screening population?. Gut 2009,
29. Neerincx M, Terhaar Sive Droste JS, Mulder CJ, Rakers M, Bartelsman JF, Loffeld RJ, Tuynman HA, Brohet RM, VAN DER Hulst RW. Colonic work-up after incomplete colonoscopy: significant new findings during follow-up. Endoscopy 2010, 42:730-735. 10.1055/s-0030-1255523, 20669092.
30. van Rossum LG, van Rijn AF, van Oijen MG, Fockens P, Laheij RJ, Verbeek AL, Jansen JB, Dekker E. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009, 125:746-750. 10.1002/ijc.24458, 19408302.
31. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96:1420-1425. 10.1093/jnci/djh275, 15467030.